Aldeyra Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aldeyra Therapeutics, Inc.
Data from a small Phase II study show that Aldeyra’s methotrexate formulation may address the underlying cause of 20%-30% of RP cases. The drug recently was denied US FDA approval in a rare ocular cancer.
The US agency is reviewing two of the US biotech’s drug with decisions expected on its methotrexate product for ocular lymphoma by June and on the dry eye drug reproxalap in November, as Aldeyra mulls its marketing strategy for both.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track: Travere’s Filspari, Chiesi’s Lamzede, Apellis’ Syfovre Headline US FDA Approvals; CRLs For Phathom, Biocon
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
- Other Names / Subsidiaries
- Aldexa Therapeutics, Inc.
- Helio Vision, Inc.
- Neuron Systems, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.